Skip to main content

Table 1 Clinical and histological data of malignant and normal adjacent breast tissues.

From: TFRC and ACTB as the best reference genes to quantify Urokinase Plasminogen Activator in breast cancer

Tissue type Age Size (mm) Tumor stage grade Histological type Menoposal status ER PR Her2/neu P53
Adjacent 50          
Adjacent 38       - - - +
Malignant 38 18 IIA III IDC pre + + -  
Malignant 38 20   III IDC pre 3+ 3+ 2+  
Malignant 58 35 IIIA II IDC post - - - +
Malignant 80 10   I IDC post + + -  
Malignant 54 30 IIB II IDC post     
Adjacent        + + 3+ +
Malignant 40 25 IIB II IDC pre + + - +
Malignant 35 20   III IDC post     
Adjacent           
Malignant        + + - +
Malignant 52 21 IIA II IDC post + + - +
Malignant    III   IDC   + - - +
Malignant 82 50 IIB III IDC post     
Adjacent 43       + + - -
Malignant 50 50 IIA II IDC pre 3+ 3+ -  
Malignant 44 20 IIIA III IDC pre + + -  
Malignant 51 20 IIA II IDC post     
Malignant        + + - -
Malignant 37 60 IIIB II IDC post     
Malignant 45     IDC pre + + -  
Malignant 40 15 IB II IDC pre - - - +
Malignant 42 20 IV III IDC pre + + - +
Malignant 52 21 IIA II IDC post + + - -
Malignant 50 8 IIA II IDC post + + -  
Malignant 54 30 IIA II IDC post - - - -
Malignant 45   IV   IDC pre     
Adjacent 45          
Adjacent 40          
Adjacent 52          
Adjacent 42       - - - -
Malignant 53     IDC+DCIS pre + + 3+ -
Malignant 34 10 IIB II IDC+DCIS pre - - - +
Malignant 56 38 IIB II IDC post + + -  
Malignant 71 20 IV II IDC post - - - -
Malignant 34 30 IIA II IDC pre + + 3+  
Malignant 37    II IDC pre - - -  
Malignant 48 30 IIB   ILC pre + + - +
Malignant 43 18 I    pre - + -  
Malignant 45 20 II II ILC pre - - 3+ +
Malignant 39 100 IIIA II IDC pre     
Malignant 34 60   III IDC pre     
Malignant           
Normal 25          
Normal 38          
Normal 32          
Normal        + + - -
Malignant 50 15 IB I IDC pre - - 3+ +
Malignant 32 10 IV II IDC pre + - -  
Malignant 60 30 IV II IDC post + + - -
Malignant 41 50 IV I IDC pre     
  1. Stage grouping are based on American Joint Committee on Cancer (AJCC). Estrogen receptor(ER), progesterone receptor (PR), Her2/neu and P53 status are based on IHC results. Invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC)